Literature DB >> 29460469

Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.

Leonie A Menke1, Thatjana Gardeitchik2, Peter Hammond3, Ketil R Heimdal4, Gunnar Houge5, Sophia B Hufnagel6, Jianling Ji7, Stefan Johansson5,8, Sarina G Kant9, Esther Kinning10, Eyby L Leon6, Ruth Newbury-Ecob11, Stefano Paolacci12, Rolph Pfundt2, Nicola K Ragge13, Tuula Rinne2, Claudia Ruivenkamp9, Sulagna C Saitta7, Yu Sun14, Marco Tartaglia15, Paulien A Terhal16, Anthony J van Essen17, Magnus D Vigeland4, Bing Xiao14, Raoul C Hennekam1.   

Abstract

In 2016, we described that missense variants in parts of exons 30 and 31 of CREBBP can cause a phenotype that differs from Rubinstein-Taybi syndrome (RSTS). Here we report on another 11 patients with variants in this region of CREBBP (between bp 5,128 and 5,614) and two with variants in the homologous region of EP300. None of the patients show characteristics typical for RSTS. The variants were detected by exome sequencing using a panel for intellectual disability in all but one individual, in whom Sanger sequencing was performed upon clinical recognition of the entity. The main characteristics of the patients are developmental delay (90%), autistic behavior (65%), short stature (42%), and microcephaly (43%). Medical problems include feeding problems (75%), vision (50%), and hearing (54%) impairments, recurrent upper airway infections (42%), and epilepsy (21%). Major malformations are less common except for cryptorchidism (46% of males), and cerebral anomalies (70%). Individuals with variants between bp 5,595 and 5,614 of CREBBP show a specific phenotype (ptosis, telecanthi, short and upslanted palpebral fissures, depressed nasal ridge, short nose, anteverted nares, short columella, and long philtrum). 3D face shape demonstrated resemblance to individuals with a duplication of 16p13.3 (the region that includes CREBBP), possibly indicating a gain of function. The other affected individuals show a less specific phenotype. We conclude that there is now more firm evidence that variants in these specific regions of CREBBP and EP300 result in a phenotype that differs from RSTS, and that this phenotype may be heterogeneous.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CBP; CREBBP; EP300; exome sequencing; genotype-phenotype correlation; intellectual disability

Mesh:

Substances:

Year:  2018        PMID: 29460469     DOI: 10.1002/ajmg.a.38626

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  14 in total

1.  Exploring by whole exome sequencing patients with initial diagnosis of Rubinstein-Taybi syndrome: the interconnections of epigenetic machinery disorders.

Authors:  Gloria Negri; Pamela Magini; Donatella Milani; Milena Crippa; Elisa Biamino; Maria Piccione; Stefano Sotgiu; Chiara Perrìa; Giuseppina Vitiello; Marina Frontali; Antonella Boni; Elisabetta Di Fede; Maria Chiara Gandini; Elisa Adele Colombo; Michael J Bamshad; Deborah A Nickerson; Joshua D Smith; Italia Loddo; Palma Finelli; Marco Seri; Tommaso Pippucci; Lidia Larizza; Cristina Gervasini
Journal:  Hum Genet       Date:  2019-02-26       Impact factor: 4.132

2.  Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.

Authors:  Elizabeth M Berry-Kravis; Mark D Harnett; Scott A Reines; Melody A Reese; Lauren E Ethridge; Abigail H Outterson; Claire Michalak; Jeremiah Furman; Mark E Gurney
Journal:  Nat Med       Date:  2021-04-29       Impact factor: 53.440

3.  A comparative analysis of KMT2D missense variants in Kabuki syndrome, cancers and the general population.

Authors:  Víctor Faundes; Geraldine Malone; William G Newman; Siddharth Banka
Journal:  J Hum Genet       Date:  2018-11-20       Impact factor: 3.172

4.  A Novel CREBBP in-Frame Deletion Variant in a Chinese Girl with Atypical Rubinstein-Taybi Syndrome Phenotypes.

Authors:  Qingming Wang; Wanfang Xu; Yanhui Liu; Haiming Yuan
Journal:  J Mol Neurosci       Date:  2020-08-25       Impact factor: 3.444

5.  Chiari 1 malformation and exome sequencing in 51 trios: the emerging role of rare missense variants in chromatin-remodeling genes.

Authors:  Aldesia Provenzano; Andrea La Barbera; Mirko Scagnet; Angelica Pagliazzi; Giovanna Traficante; Marilena Pantaleo; Lucia Tiberi; Debora Vergani; Nehir Edibe Kurtas; Silvia Guarducci; Sara Bargiacchi; Giulia Forzano; Rosangela Artuso; Viviana Palazzo; Ada Kura; Flavio Giordano; Daniele di Feo; Marzia Mortilla; Claudio De Filippi; Gianluca Mattei; Livia Garavelli; Betti Giusti; Lorenzo Genitori; Orsetta Zuffardi; Sabrina Giglio
Journal:  Hum Genet       Date:  2020-12-18       Impact factor: 4.132

Review 6.  Reprogramming of the epigenome in neurodevelopmental disorders.

Authors:  Khadija D Wilson; Elizabeth G Porter; Benjamin A Garcia
Journal:  Crit Rev Biochem Mol Biol       Date:  2021-10-02       Impact factor: 8.697

7.  Three-dimensional facial morphology in Cantú syndrome.

Authors:  Helen I Roessler; Kathleen Shields; Dorothy K Grange; Nine V A M Knoers; Gijs van Haaften; Peter Hammond; Mieke M van Haelst
Journal:  Am J Med Genet A       Date:  2020-02-26       Impact factor: 2.802

8.  The development of early social cognitive skills in neurogenetic syndromes associated with autism: Cornelia de Lange, fragile X and Rubinstein-Taybi syndromes.

Authors:  Katherine Ellis; Jo Moss; Chrysi Stefanidou; Chris Oliver; Ian Apperly
Journal:  Orphanet J Rare Dis       Date:  2021-11-22       Impact factor: 4.123

Review 9.  Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.

Authors:  Julien Van Gils; Frederique Magdinier; Patricia Fergelot; Didier Lacombe
Journal:  Genes (Basel)       Date:  2021-06-24       Impact factor: 4.096

10.  Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders.

Authors:  Michael A Levy; Haley McConkey; Jennifer Kerkhof; Mouna Barat-Houari; Sara Bargiacchi; Elisa Biamino; María Palomares Bralo; Gerarda Cappuccio; Andrea Ciolfi; Angus Clarke; Barbara R DuPont; Mariet W Elting; Laurence Faivre; Timothy Fee; Robin S Fletcher; Florian Cherik; Aidin Foroutan; Michael J Friez; Cristina Gervasini; Sadegheh Haghshenas; Benjamin A Hilton; Zandra Jenkins; Simranpreet Kaur; Suzanne Lewis; Raymond J Louie; Silvia Maitz; Donatella Milani; Angela T Morgan; Renske Oegema; Elsebet Østergaard; Nathalie Ruiz Pallares; Maria Piccione; Simone Pizzi; Astrid S Plomp; Cathryn Poulton; Jack Reilly; Raissa Relator; Rocio Rius; Stephen Robertson; Kathleen Rooney; Justine Rousseau; Gijs W E Santen; Fernando Santos-Simarro; Josephine Schijns; Gabriella Maria Squeo; Miya St John; Christel Thauvin-Robinet; Giovanna Traficante; Pleuntje J van der Sluijs; Samantha A Vergano; Niels Vos; Kellie K Walden; Dimitar Azmanov; Tugce Balci; Siddharth Banka; Jozef Gecz; Peter Henneman; Jennifer A Lee; Marcel M A M Mannens; Tony Roscioli; Victoria Siu; David J Amor; Gareth Baynam; Eric G Bend; Kym Boycott; Nicola Brunetti-Pierri; Philippe M Campeau; John Christodoulou; David Dyment; Natacha Esber; Jill A Fahrner; Mark D Fleming; David Genevieve; Kristin D Kerrnohan; Alisdair McNeill; Leonie A Menke; Giuseppe Merla; Paolo Prontera; Cheryl Rockman-Greenberg; Charles Schwartz; Steven A Skinner; Roger E Stevenson; Antonio Vitobello; Marco Tartaglia; Marielle Alders; Matthew L Tedder; Bekim Sadikovic
Journal:  HGG Adv       Date:  2021-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.